amlodipine has been researched along with Kidney Failure, Chronic in 72 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 9.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Amlodipine, not aliskiren, effectively reduces BP in CKD patients with refractory hypertension undergoing HD." | 9.19 | Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. ( Hara, Y; Hosoya, T; Kuriyama, S; Sugano, N; Yokoo, T; Yokoyama, K, 2014) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 9.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 9.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 9.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina." | 7.78 | Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. ( Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)." | 6.71 | Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005) |
| "Insulin resistance (IR) in chronic renal failure (CRF) is well-known." | 6.70 | Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002) |
| "Dialysate effluent leukocytosis is consistent with a greater degree of infection or inflammation in patients receiving peritoneal dialysis." | 5.35 | Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate. ( Lee, F; Yu, MC, 2009) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 5.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Amlodipine, not aliskiren, effectively reduces BP in CKD patients with refractory hypertension undergoing HD." | 5.19 | Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. ( Hara, Y; Hosoya, T; Kuriyama, S; Sugano, N; Yokoo, T; Yokoyama, K, 2014) |
| "Ramipril attenuates renal Fibroblast growth factor-23 (FGF-23) expression, ameliorates proteinuria and normalizes serum phosphate in the diabetic Zucker rat with progressive renal disease suggesting that the renoprotective effect by this drug may be in part due to a FGF-23-lowering effect of angiotensin-converting enzyme (ACE) inhibition." | 5.19 | Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. ( Cetinkaya, H; Eyileten, T; Gok, M; Karaman, M; Kurt, YG; Mallamaci, F; Oguz, Y; Saglam, M; Sonmez, A; Unal, HU; Vural, A; Yilmaz, MI; Zoccali, C, 2014) |
| "The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals." | 5.16 | Renal outcomes in hypertensive Black patients at high cardiovascular risk. ( Bakris, GL; Dahlof, B; Devereux, RB; Hester, RA; Hua, TA; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, E; Weber, MA; Weir, MR; Wright, JT, 2012) |
| "There was evidence of pharmacogenetic effects of FGB-455 on stroke, ESRD, and mortality, suggesting that relative to those homozygous for the common allele, variant allele carriers of the FGB gene at position -455 have a better outcome if randomized to lisinopril than chlorthalidone (for mortality and ESRD) or amlodipine (for mortality and stroke)." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
| "We examined the effects of 2 calcium channel blockers, benidipine (T-, L-, and N-type) and amlodipine (L- and N-type), on renal, inflammatory, oxidative, and atherosclerosis markers in hypertensive patients with mild chronic kidney disease (CKD)." | 5.14 | Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y; Yamada, S; Yamagishi, S, 2010) |
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "BP control with ramipril or amlodipine could not provide adequate protection for development or progression of atherosclerosis and eccentric type of LVH in nondiabetic HD patients." | 5.14 | Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. ( Akinci, D; Altun, B; Kahraman, S; Ozer, N; Turgan, C; Yilmaz, R, 2010) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| " Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model." | 5.11 | An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. ( Annemans, L; Bilous, RW; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| " Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4." | 5.11 | Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, M; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2005) |
| "The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] < or =92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol)." | 5.11 | Blood pressure control, drug therapy, and kidney disease. ( Agodoa, LY; Cheek, D; Contreras, G; Dowie, D; Greene, T; Junco, G; Lash, J; Lipkowitz, M; Miller, ER; Ojo, A; Sika, M; Toto, RD; Wilkening, B, 2005) |
| "High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications." | 5.10 | The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 5.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "We studied muscle sympathetic-nerve activity in 14 patients with hypertension, chronic renal failure, and increased plasma renin activity before, during, and after administration of the ACE inhibitor enalapril." | 5.09 | Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. ( Blankestijn, PJ; Boomsma, F; Dijkhorst-Oei, LT; Klein, IH; Koomans, HA; Ligtenberg, G; Oey, PL; van Huffelen, AC; Wieneke, GH, 1999) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 5.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "Treatment of hypertension with CCBs should take into consideration the special effects of each single agent at different levels; lercanidipine for example may play a useful role in the management not only of hypertension but also in renal protection of hypertensive patients." | 4.89 | Renal protection with calcium antagonists: the role of lercanidipine. ( Burnier, M, 2013) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| "Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina." | 3.78 | Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. ( Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012) |
| "Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in the United States, and accounts for 35% of all the patients with ESRD entering a dialysis program; 63% of patients with diabetic nephropathy have type II diabetes mellitus." | 3.78 | Renoprotection and renin-angiotensin system blockade in diabetes mellitus. ( Ruilope, LM, 1997) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "Treating patients with hypertension, type 2 diabetes and nephropathy using irbesartan lowers the cumulative incidence of ESRD and is cost-saving compared to amlodipine or control." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors." | 2.72 | Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. ( Aslam, S; Leone, A; Santha, T; Wilcox, C, 2006) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| "Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2." | 2.71 | Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for ( Hayashi, M; Ideura, T; Iino, Y; Kawaguchi, Y; Kawamura, T; Kitajima, T; Koyama, A; Kuwahara, M; Shiigai, T; Sugisaki, T; Suzuki, H; Tomino, Y; Uchida, S; Umemura, S; Yamada, K; Yamazaki, T, 2003) |
| "Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)." | 2.71 | Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Insulin resistance (IR) in chronic renal failure (CRF) is well-known." | 2.70 | Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002) |
| "Hypertension is the second leading attributable cause of end-stage renal disease in the United States today." | 2.43 | Lessons from the African-American Study of Kidney Disease and Hypertension: an update. ( Toto, RD, 2006) |
| "Patients with type 2 diabetes and diabetic nephropathy have a dramatically increased cardiovascular risk." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "The association was similar when ESRD and a 50% decline in eGFR were analyzed separately, for other measures of visit-to-visit variability of systolic BP, and for visit-to-visit variability of diastolic BP." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| "The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present." | 1.43 | Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. ( Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016) |
| "In patients with established Type 2 diabetic nephropathy and CKD Stages 1-5, irbesartan safely and significantly slowed the rate of ΔeGFR decline (-2." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| "Dialysate effluent leukocytosis is consistent with a greater degree of infection or inflammation in patients receiving peritoneal dialysis." | 1.35 | Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate. ( Lee, F; Yu, MC, 2009) |
| "Both in CHF (congestive heart failure) and CRI (chronic renal insufficiency), blood pressure reduction is beneficial for preservation of cardiac and renal function." | 1.31 | Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency. ( Ikeda, N; Kanno, Y; Moriwaki, K; Nakamoto, H; Okada, H; Sugahara, S; Suzuki, H, 2002) |
| "Proteinuria was reduced with both drugs." | 1.31 | Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure. ( Kanno, Y; Okada, H; Saruta, T; Suzuki, H; Takenaka, T, 2000) |
| "It is concluded that chronic renal failure is associated with deranged calcium homeostasis of PMNLs which causes abnormalities in the function of Fcgamma RIII receptors and consequently results in impaired phagocytosis." | 1.30 | Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients. ( Ahmed, A; Krol, E; Massry, SG; Smogorzewski, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.94) | 18.2507 |
| 2000's | 44 (61.11) | 29.6817 |
| 2010's | 22 (30.56) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Youssef, AM | 1 |
| Elghoneimy, HA | 1 |
| Helmy, MW | 1 |
| Abdelazeem, AM | 1 |
| El-Khodary, NM | 1 |
| Zahed, NS | 1 |
| Hassanian-Moghaddam, H | 1 |
| Zamani, N | 1 |
| Jeon, SY | 1 |
| Lee, NR | 1 |
| Yim, CY | 1 |
| Aldemir, NM | 1 |
| Begenik, H | 1 |
| Emre, H | 1 |
| Erdur, FM | 1 |
| Soyoral, Y | 1 |
| Burnier, M | 2 |
| Kuriyama, S | 1 |
| Yokoyama, K | 1 |
| Hara, Y | 1 |
| Sugano, N | 1 |
| Yokoo, T | 1 |
| Hosoya, T | 1 |
| Uchida, S | 3 |
| Takahashi, M | 1 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Fujita, M | 1 |
| Mochizuki, K | 1 |
| Shin, I | 1 |
| Morita, T | 1 |
| Hikita, T | 1 |
| Itakura, H | 1 |
| Takahashi, Y | 1 |
| Mizuno, S | 1 |
| Ohno, Y | 1 |
| Ito, K | 1 |
| Ito, T | 1 |
| Soma, M | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Saglam, M | 1 |
| Kurt, YG | 1 |
| Unal, HU | 1 |
| Karaman, M | 1 |
| Gok, M | 1 |
| Cetinkaya, H | 1 |
| Eyileten, T | 1 |
| Oguz, Y | 1 |
| Vural, A | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 2 |
| Statsenko, ME | 1 |
| Derevyanchenko, MV | 1 |
| Whittle, J | 1 |
| Lynch, AI | 2 |
| Tanner, RM | 1 |
| Simpson, LM | 1 |
| Davis, BR | 5 |
| Rahman, M | 5 |
| Whelton, PK | 4 |
| Oparil, S | 2 |
| Muntner, P | 1 |
| Robertson, LM | 1 |
| Frith, JA | 1 |
| Tcheurekdjian, H | 1 |
| Hostoffer, RW | 1 |
| Al-Ramahi, R | 1 |
| Raddad, AR | 1 |
| Rashed, AO | 1 |
| Bsharat, A | 1 |
| Abu-Ghazaleh, D | 1 |
| Yasin, E | 1 |
| Shehab, O | 1 |
| Moes, AD | 1 |
| Hesselink, DA | 1 |
| van den Meiracker, AH | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Guo, LL | 1 |
| Pan, Y | 1 |
| Jin, HM | 1 |
| Lee, F | 1 |
| Yu, MC | 1 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, T | 1 |
| Maruyama, N | 1 |
| Matsumoto, K | 1 |
| Wallace, EL | 1 |
| Lingle, K | 1 |
| Pierce, D | 1 |
| Satko, S | 1 |
| Boerwinkle, E | 1 |
| Ford, CE | 2 |
| Eckfeldt, JH | 3 |
| Leiendecker-Foster, C | 1 |
| Arnett, DK | 1 |
| Nakamura, T | 2 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Kawagoe, Y | 2 |
| Ueda, Y | 2 |
| Sugaya, T | 2 |
| Yamagishi, S | 1 |
| Yamada, S | 1 |
| Koide, H | 2 |
| Heerspink, HL | 1 |
| de Zeeuw, D | 1 |
| Bakris, GL | 4 |
| Sarafidis, PA | 1 |
| Weir, MR | 2 |
| Dahlöf, B | 2 |
| Pitt, B | 2 |
| Jamerson, K | 3 |
| Velazquez, EJ | 1 |
| Staikos-Byrne, L | 1 |
| Kelly, RY | 2 |
| Shi, V | 1 |
| Chiang, YT | 1 |
| Weber, MA | 2 |
| Schorn, R | 1 |
| Gaspert, A | 1 |
| Cohen, CD | 1 |
| Nakano, N | 1 |
| Ishimitsu, T | 1 |
| Takahashi, T | 1 |
| Inada, H | 1 |
| Okamura, A | 1 |
| Ohba, S | 1 |
| Matsuoka, H | 1 |
| Yilmaz, R | 1 |
| Altun, B | 2 |
| Kahraman, S | 1 |
| Ozer, N | 1 |
| Akinci, D | 1 |
| Turgan, C | 1 |
| Takano, H | 1 |
| Hasegawa, H | 1 |
| Narumi, H | 1 |
| Shindo, S | 1 |
| Mizuma, H | 1 |
| Kuwabara, Y | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 2 |
| Devereux, RB | 1 |
| Kjeldsen, SE | 1 |
| Wright, JT | 6 |
| Hua, TA | 1 |
| Hester, RA | 1 |
| Velazquez, E | 1 |
| Jamerson, KA | 1 |
| Cutler, JA | 1 |
| Piller, LB | 1 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Haywood, LJ | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Shibasaki, Y | 3 |
| Nishiue, T | 3 |
| Masaki, H | 3 |
| Matsubara, H | 3 |
| Iwasaka, T | 3 |
| Suzuki, H | 6 |
| Bakris, G | 1 |
| Greene, T | 3 |
| Agodoa, LY | 3 |
| Appel, LJ | 1 |
| Charleston, J | 2 |
| Cheek, D | 3 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 2 |
| Glassock, R | 1 |
| Hebert, L | 2 |
| Lewis, J | 1 |
| Phillips, RA | 2 |
| Toto, RD | 5 |
| Middleton, JP | 1 |
| Rostand, SG | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Yildiz, A | 1 |
| Hursit, M | 1 |
| Celik, AV | 1 |
| Kayacan, SM | 1 |
| Yazici, H | 1 |
| Akkaya, V | 1 |
| Gürol, AO | 1 |
| Karsidag, K | 1 |
| Fukuda, M | 1 |
| Usami, T | 1 |
| Yoshida, A | 1 |
| Kimura, G | 1 |
| Berl, T | 2 |
| Hunsicker, LG | 2 |
| Lewis, JB | 4 |
| Pfeffer, MA | 1 |
| Porush, JG | 1 |
| Rouleau, JL | 1 |
| Drury, PL | 1 |
| Esmatjes, E | 1 |
| Hricik, D | 1 |
| Parikh, CR | 1 |
| Raz, I | 2 |
| Vanhille, P | 1 |
| Wiegmann, TB | 1 |
| Wolfe, BM | 1 |
| Locatelli, F | 1 |
| Goldhaber, SZ | 1 |
| Lewis, EJ | 3 |
| Odabas, AR | 1 |
| Cetinkaya, R | 1 |
| Selcuk, Y | 1 |
| Keles, S | 1 |
| Bilen, H | 1 |
| Morrone, LF | 1 |
| Ramunni, A | 1 |
| Fassianos, E | 1 |
| Saracino, A | 1 |
| Coratelli, P | 1 |
| Passavanti, G | 1 |
| Iino, Y | 2 |
| Hayashi, M | 2 |
| Kawamura, T | 2 |
| Shiigai, T | 2 |
| Tomino, Y | 2 |
| Yamada, K | 2 |
| Kitajima, T | 2 |
| Ideura, T | 2 |
| Koyama, A | 2 |
| Sugisaki, T | 2 |
| Umemura, S | 2 |
| Kawaguchi, Y | 1 |
| Kuwahara, M | 2 |
| Yamazaki, T | 2 |
| Palmer, AJ | 3 |
| Annemans, L | 2 |
| Roze, S | 2 |
| Lamotte, M | 2 |
| Rodby, RA | 2 |
| Ritz, E | 2 |
| Ruilope, LM | 2 |
| Segura, J | 1 |
| Kawaguchii, Y | 1 |
| McCullough, PA | 1 |
| Pressel, S | 2 |
| Nwachuku, C | 2 |
| Barzilay, J | 2 |
| Batuman, V | 2 |
| Farber, M | 1 |
| Henriquez, M | 2 |
| Kopyt, N | 2 |
| Louis, GT | 2 |
| Saklayen, M | 2 |
| Stanford, C | 2 |
| Walworth, C | 2 |
| Ward, H | 2 |
| Wiegmann, T | 2 |
| Contreras, G | 1 |
| Junco, G | 1 |
| Dowie, D | 2 |
| Lash, J | 2 |
| Lipkowitz, M | 2 |
| Miller, ER | 2 |
| Ojo, A | 2 |
| Sika, M | 1 |
| Wilkening, B | 1 |
| MacGregor, MS | 1 |
| Deighan, CJ | 1 |
| Rodger, RS | 1 |
| Boulton-Jones, JM | 1 |
| Formica, RN | 1 |
| Friedman, AL | 1 |
| Lorber, MI | 1 |
| Smith, JD | 1 |
| Eisen, T | 1 |
| Bia, MJ | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Tamura, K | 1 |
| Matsumoto, N | 1 |
| Mori, Y | 1 |
| Nishikawa, M | 2 |
| Frei, A | 1 |
| Hess, B | 1 |
| Aslam, S | 1 |
| Santha, T | 1 |
| Leone, A | 1 |
| Wilcox, C | 1 |
| Suzuki, T | 1 |
| Inoue, T | 1 |
| Node, K | 1 |
| Yee, J | 1 |
| August, P | 1 |
| Lenz, T | 1 |
| Laragh, JH | 1 |
| Ligtenberg, G | 1 |
| Blankestijn, PJ | 1 |
| Oey, PL | 1 |
| Klein, IH | 1 |
| Dijkhorst-Oei, LT | 1 |
| Boomsma, F | 1 |
| Wieneke, GH | 1 |
| van Huffelen, AC | 1 |
| Koomans, HA | 1 |
| Ahmed, A | 1 |
| Krol, E | 1 |
| Smogorzewski, M | 1 |
| Massry, SG | 1 |
| Usalan, C | 1 |
| Erdem, Y | 1 |
| Arici, M | 1 |
| Kanno, Y | 2 |
| Okada, H | 2 |
| Takenaka, T | 1 |
| Saruta, T | 1 |
| Appel, L | 1 |
| Beck, G | 1 |
| Bourgoignie, J | 1 |
| Briggs, JP | 1 |
| Cleveland, W | 1 |
| Douglas, JG | 1 |
| Douglas, M | 1 |
| Faulkner, M | 1 |
| Gabriel, A | 1 |
| Hall, Y | 1 |
| Hiremath, L | 1 |
| Johnson, CJ | 1 |
| Kopple, J | 1 |
| Kusek, J | 1 |
| Lea, J | 1 |
| Massry, S | 1 |
| Middleton, J | 1 |
| Norris, K | 1 |
| O'Connor, D | 1 |
| Pogue, V | 1 |
| Randall, OS | 1 |
| Rostand, S | 1 |
| Schulman, G | 1 |
| Smith, W | 1 |
| Thornley-Brown, D | 1 |
| Tisher, CC | 1 |
| Xu, S | 1 |
| Vidt, DG | 1 |
| Clarke, WR | 1 |
| Pohl, MA | 1 |
| Atkins, RC | 1 |
| Rohde, R | 1 |
| McConaghy, JR | 1 |
| Ikeda, N | 1 |
| Moriwaki, K | 1 |
| Sugahara, S | 1 |
| Nakamoto, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.[NCT04085562] | Phase 4 | 46 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| [NCT01738945] | Phase 4 | 32 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395] | Phase 3 | 49 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
9 reviews available for amlodipine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Renal protection with calcium antagonists: the role of lercanidipine.
Topics: Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Kidney Failure | 2013 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium; | 2006 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
40 trials available for amlodipine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypert | 2021 |
Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Fumarates; Huma | 2014 |
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini | 2014 |
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type | 2014 |
[Cardio-Nephroprotection--the Most Important Goal of Antihypertensive Therapy in Patients With Type 2 Diabetes].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 2015 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Dihydropyridine | 2009 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Atherosclerosis; Biomarkers; Calcium Channel Blocker | 2010 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients.
Topics: Aged; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; C | 2010 |
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Carotid Arteries; Female; Heart V | 2010 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Doxazosin; Female; Homeostasis; Humans; Insulin Resistan | 2002 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response | 2003 |
Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2003 |
Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension--a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Japan; Kidney Failur | 2004 |
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diab | 2004 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Blood pressure control, drug therapy, and kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
A prospective open-label randomised trial of quinapril and/or amlodipine in progressive non-diabetic renal failure.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blocker | 2005 |
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relati | 2006 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Collagen; Double-Blind Method; Echocardiography | 2005 |
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood | 2006 |
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressu | 2007 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Baroreflex; Calcium Channel Blockers; Enalapri | 1999 |
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatinine; Humans; H | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Double-Blind Method; Female; Glomeru | 2001 |
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihy | 2002 |
24 other studies available for amlodipine and Kidney Failure, Chronic
| Article | Year |
|---|---|
A Fatal Case of Amlodipine Toxicity Following Iatrogenic Hypercalcemia.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Calcium Gluconate; Electrocardiography; Fatal Outcome; | 2018 |
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma | 2019 |
Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Gingival Hyperplasia; Humans; Hypertension; Kidney Fail | 2012 |
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
Possible mast cell activation syndrome in a patient undergoing long-term hemodialysis.
Topics: Aged; Amlodipine; Anaphylaxis; Carbazoles; Carvedilol; Community-Acquired Infections; Deglutition Di | 2016 |
Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arabs; Aspirin; Calcium Carbonate; Comorbidity; Diabetes | 2016 |
Association between peritoneal dialysate effluent leukocytosis and amlodipine besylate.
Topics: Amlodipine; Calcium Channel Blockers; Child, Preschool; Dialysis Solutions; Female; Humans; Kidney F | 2009 |
Amlodipine-induced myoclonus.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clonidine; Diuretics; Humans; H | 2009 |
Composite renal endpoints: was ACCOMPLISH accomplished?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2010 |
[Anti-RNA polymerase III antibodies in scleroderma renal crisis].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2010 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Antihypertensive drugs and renal protection.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Nitrendipine and amlodipine mimic the acute effects of enalapril on renal haemodynamics and reduce glomerular hyperfiltration in patients with chronic kidney disease.
Topics: Adult; Amlodipine; Enalapril; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney Failu | 2003 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
[Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diabetes | 2004 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure.
Topics: Amlodipine; Antihypertensive Agents; Dipeptides; Hemodynamics; Humans; Kidney Failure, Chronic; Lisi | 1993 |
Effect of amlodipine therapy on the monoclonal antibody 3G8-induced calcium signal in polymorphonuclear leukocytes of hemodialysis patients.
Topics: Adult; Amlodipine; Antibodies, Monoclonal; Calcium Channel Blockers; Calcium Signaling; Female; Huma | 1999 |
Severe thrombocytopenia associated with amlodipine treatment.
Topics: Adult; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension, Renal; Kidney Failure, Chr | 1999 |
Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressu | 2000 |
Intensive blood pressure reduction is beneficial in patients with impaired cardiac function coexisting with chronic renal insufficiency.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Crea | 2002 |